Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2022-02-08 Earnings Release
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
KOLINPHARMA, CDA APPROVA KPI 4Q 2021 E RICAVI 2021
Earnings Release Classification · 1% confidence The document is a regulatory announcement (Informazione Regolamentata) from KOLINPHARMA dated February 8, 2022. The subject is '2021 E RICAVI 2021' (2021 Revenues and 2021 Revenues) and it provides preliminary revenue figures for the full year 2021 (€11.2 million, +36% vs FY 2020) and KPI data for Q4 2021 prescriptions. It also announces the approval of KPIs, the start of a share buyback program, and the identification of beneficiaries for stock option plans. Since this document announces preliminary financial results (Ricavi preliminari) and key performance indicators (KPIs) for a period, it fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it contains other corporate actions (share buyback), the primary focus and headline relate to the financial performance announcement. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather the initial release of results. FY 2021
2022-02-08 Italian
KOLINPHARMA, OTTIENE PRIMO BREVETTO IN ITALIA PER IL DOLTENDIX, 45° NEL PORTAFOGLIO BREVETTI.
Regulatory Filings Classification · 1% confidence The document is a formal communication released on January 27, 2022, identified as 'Informazione Regolamentata' (Regulated Information) on Euronext Growth Milan. The subject ('Oggetto') is 'KOLINPHARMA, OTTIENE PRIMO BREVETTO IN ITALIA PER IL BREVETTI. DOLTENDIX, 45° NEL PORTAFOGLIO'. The content details the granting of a patent for the product DOLTENDIX® and notes that the total number of patents held by the company is now 45. This is a specific announcement regarding intellectual property and innovation, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate event announcement. Since there is no specific category for 'Patent Grant Announcement', and it is a material, non-financial regulatory disclosure, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific corporate news that doesn't fit the other defined categories (like DIRS, DIV, CAP, etc.). Given the nature of the announcement (patent grant), it is a specific piece of corporate news released via regulatory channels.
2022-01-27 Italian
KOLINPHARMA, CALENDARIO EVENTI SOCIETARI 2022
Regulatory Filings Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from KOLINPHARMA, dated January 25, 2022. The subject ('Oggetto') is 'SOCIETARI 2022' and the content explicitly details the 'calendario degli eventi societari dell'esercizio 2022' (calendar of corporate events for the year 2022). This calendar includes dates for Board meetings, shareholder meetings (Assemblea degli Azionisti), and financial reporting milestones (like budget approval and semi-annual reports). This type of forward-looking schedule announcement, which is not a full report itself (like 10-K or IR) but rather an announcement about future corporate actions and reporting dates, fits best under the general category of regulatory announcements or filings that inform investors about upcoming events. Since it is a specific announcement about corporate events rather than a general regulatory filing (RNS) or a specific report type, and given the options, it is a notification about future corporate activities. However, since it is a formal announcement published via the regulatory channel (Euronext Growth Milan) detailing future corporate governance and reporting dates, it functions as a general regulatory disclosure. Given the options, 'RNS' (Regulatory Filings - general fallback) is appropriate, but 'RPA' (Report Publication Announcement) is often used for announcements about future reports. Since this announcement covers the entire year's schedule including board meetings and AGMs, it is a broad corporate event calendar announcement. In the context of Italian regulatory filings, this is often classified as a general disclosure. Given the options, and since it is not announcing the *publication* of a specific report but rather the *schedule* of events, 'RNS' (Regulatory Filings) serves as the most appropriate general category for this type of mandatory corporate calendar disclosure that doesn't fit a more specific category like DIV or DVA.
2022-01-25 Italian
KOLINPHARMA, OTTIENE LA CERTIFICAZIONE AMBIENTALE ISO 14001
Environmental & Social Information Classification · 1% confidence The document is an official communication from KOLINPHARMA dated January 19, 2022, announcing that the company has obtained the ISO 14001 environmental certification. The subject line explicitly states: 'KOLINPHARMA, OTTIENE LA CERTIFICAZIONE AMBIENTALE ISO 14001'. The content details ESG compliance efforts, including the new certification, the 'Foresta Kolinpharma' project, and the purchase of a defibrillator. This type of announcement, focusing on environmental, social, and governance performance metrics and achievements (like obtaining an ISO certification), aligns directly with the definition of Environmental & Social Information (ESG reporting). It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), but specifically addresses ESG factors.
2022-01-19 Italian
KOLINPHARMA, L'ASSEMBLEA DEGLI AZIONISTI APPROVA L'AUMENTO DI CAPITALE A SERVIZIO DEI PIANI DI INCENTIVAZIONE
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement ('Informazione Regolamentata') from KOLINPHARMA dated December 20, 2021. The subject ('Oggetto') explicitly states that the Shareholders' Meeting approved a capital increase ('aumento di capitale') to service incentive plans (Stock Options). This action directly relates to changes in the company's capital structure and fundraising activities, specifically through issuing shares to employees as part of incentive schemes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves shareholder approval, the core subject is the capital increase mechanism itself, rather than just the voting results (DVA) or a general AGM presentation (AGM-R).
2021-12-20 Italian
KOLINPHARMA, APPROVAZIONE DEI NUOVI PIANI DI INCENTIVAZIONE
Remuneration Information Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from KOLINPHARMA dated December 2, 2021, published on Euronext Growth Milan. The subject ('Oggetto') is 'NUOVI PIANI DI INCENTIVAZIONE' (New Incentive Plans). The text details the approval of two employee incentive plans (Stock Option Plan and Stock Option Retention Plan) by the Board of Directors. It also mentions proposing a capital increase to shareholders via an extraordinary meeting to support these plans. This content relates directly to changes in the company's capital structure and employee incentive schemes, which often fall under financing activities or capital changes. Since the core subject is the approval of new incentive plans tied to stock options and a related capital increase proposal, the most fitting category is 'Capital/Financing Update' (CAP). It is not a standard earnings release (ER), an annual report (10-K), or a simple dividend notice (DIV).
2021-12-02 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.